Pharmaceutical Research and Manufacturers of America (PhRMA) issued a statement today recognizing World Anti-Counterfeiting Day.
In an effort to make the public aware of the threat that counterfeit medicines posed to patient health and safety, PhRMA President and CEO John J. Castellani noted:
“As we recognize World Anti-Counterfeiting Day today, we must remember all that is at stake if we do not continue to crack down on life-threatening counterfeit medicine crimes. Make no mistake, the counterfeit medicine epidemic is a very real threat that puts millions of patients’ lives at risk. Fortunately, in the U.S., our lines of defense are strong because the closed and carefully regulated drug supply system represents an important protection for the American public against the massive influx of foreign counterfeit medicines.”
AstraZeneca sent a letter to members of Congress in January to express support for legislation that would increase penalties for those convicted of counterfeiting prescription medicines. In March, the Senate passed a bill that would increase penalties for those convicted.
“Now, more than ever, public and private partners — U.S. law enforcement, government agencies and industry — must continue to work together to combat these dangerous counterfeiting crimes. Just as the G8 recently issued a declaration recognizing the threat of the growing counterfeit medicine trade, U.S. policymakers must focus on ways we can continue to protect our closed supply chain and prevent counterfeit medicines from harming American patients.”
AstraZeneca will continue to work with members of Congress and the Administration to help safeguard the U.S. drug supply system, including seeking stronger penalties for those who counterfeit the medicines our companies research and develop.